qSerum cholesterol reduction & IHDFƑ87H Ne823 Jan 2007 20:26idal idsmmrreg_0qgw`cgidbmjamez[!!Iwdrop _allatrialnameinterventionihdentrycholreducsclreducfclreducnclreducselreducfelreduconnelreducororrlogorrselogorionvarlogorion%9.0g%8.0g%9.0g%16s%9.0g%25.0g%9.0g%9.0g%9.0g%8.0g%9.0g%9.0g%8.0g%9.0g%9.0g%9.0g%9.0g(198):r(198);}}ed fte(198):r(198);}}ed fte(198):r(198);}}ed fteintihdnthdntrventionhdnihdID in Stat Med 1999 each cell in trials where any cell is zero to calculate or, ID in Stat Meth Med Res 1993l in trials where any cell is zero to calculate or, ID in BMJ 1994 Med Res 1993l in trials where any cell is zero to calculate or, Trial name994 Med Res 1993l in trials where any cell is zero to calculate or, Intervention typed Res 1993l in trials where any cell is zero to calculate or, Ischaemic heart disease on entry trials where any cell is zero to calculate or, Cholesterol reduction (mmol/l)y trials where any cell is zero to calculate or, Control group Events (mmol/l)y trials where any cell is zero to calculate or, Control group No eventsmol/l)y trials where any cell is zero to calculate or, Control group totalntsmol/l)y trials where any cell is zero to calculate or, Treated group Eventstsmol/l)y trials where any cell is zero to calculate or, Treated group No eventsmol/l)y trials where any cell is zero to calculate or, Treated group totalntsmol/l)y trials where any cell is zero to calculate or, Odds ratioup totalntsmol/l)y trials where any cell is zero to calculate or, Log-odds ratiootalntsmol/l)y trials where any cell is zero to calculate or, SE of Log-odds ratiotsmol/l)y trials where any cell is zero to calculate or, Variance of Log-odds ratio/l)y trials where any cell is zero to calculate or, _dta `0't }s non-fatal inidsmmnote4daZ…De0.5 added to each cell in trials where any cell is zero to calculate or, logor, selogor, varlogor.D_dta `0't }s non-fatal inidsmmnote0daZ…D4H_dta `0't }s non-fatal inidsmm__xi__Vars__Prefix__=Q[_I _I\_dta `0't }s non-fatal inidsmm__xi__Vars__To__Drop__=Q[_Iihdentry_1 _Iihdentry_2J_dta `0't }s non-fatal inidsmm_lang_cFX(bJ=Q[defaultJ_dta `0't }s non-fatal inidsmm_lang_list(bJ=Q[defaultDida `0't }s non-fatal inidsmmnote0FX(bD=Q[1ida `0't }s non-fatal inidsmmnote1FX(b=Q['Trial' column in Table 1 of Thompson & Sharp, Stat Med 1999; 18:2693-2708Dihdentryt }s non-fatal inidsmmnote0FX(bD=Q[1zihdentryt }s non-fatal inidsmmnote1FX(bz=Q[Angina or previous non-fatal infarction (BMJ 1994 p368)Didsmmryt }s non-fatal inidsmmnote0FX(bD=Q[1idsmmryt }s non-fatal inidsmmnote1FX(b=Q['Trial' column in Table 2 of Thompson, Stat Methods Med Res 1993; 2:173-192Didbmjyt }s non-fatal inidsmmnote0FX(bD=Q[1idbmjyt }s non-fatal inidsmmnote1FX(b=Q[Order in Table IV of Law, Wald & Thompson, BMJ 1994; 308:376-372y_dtayt }s non-fatal inidsmmnote1FX(by=Q[Data from Thompson & Sharp Stat Med 1999; 18:2693-2708_dtayt }s non-fatal inidsmmnote2FX(b=Q[First published in Law, M.R. Wald & Thompson BMJ 1994; 308:367-372_dtayt }s non-fatal inidsmmnote3FX(b=Q[25 / 28 trials also in Thompson, Stat Methods Med Res 1993; 2:173-192WHOastlepidls ?&O?Tm#=?3< Newcastlepidls{.?U6?gP>)=ScottishpidlsY?K$o6(^F5?)SI>T=CDPpidls ?=  ]?)Lz=׸t; VA drug-lipidls= ?E*gO?.8u>pj>LW= StockholmLls= W?eIx/?oH=> =LRC앗Llsff&?lru?K?Jl=6P< NHLBI앗LlsY? =HAG ?"n+ ?/&> Upjohn앗LlsH>*?i$Y}{MV?6l>Z= McCaughanLls{.?VX>`?N? Helsinki w/o IHDף0?T8y&?Tܾ3> <  CLAS앗Lls̬?Y^]^C>ӿ~? j? MinnesotaLls333?y+:o?=>W< Los AngelesLlsR^?Ae4tD?R[M>D$=MRC앗Lls33s?4-FL?gp>;a= Oslo앗Llsף?Q=)?bҾ~yP>)=Sydney앗LlsR>%No?G?>n=St Mary'sLls(? )4־?U|>m ?>London Hospitals?2T/Ss?cLÂ>=POSCH앗L= ?}$RS ?"&><EXCEL앗Lq=?k>xzG? |k>-=FATS앗Lp?44\^#5@j?ņ?͂@ Gross앗L)\?{@\K?@?;/@STARS앗L?9<>PᪿD?C?DART앗L>gvf?9+ս>Й<eHelsinki w. IHD\B?%=#7 *?>S>A=eSahni앗Lq= ?JNLO:?tG?F)?eBegg앗L{.?<OEL>4>sh>2int$w/8=H`N, DrugDietSurgeryOihdnihd/8=H`N,/Without known IHDWith IHDWith or without IHD